# EDGAR Filing Document

**Accession Number:** 0001676725
**File Stem:** 0001193125-23-067903
**Filing Date:** 2023-3
**Character Count:** 5759
**Document Hash:** 06fe1987e5904c88e55d5da62e8090c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-067903.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001193125-23-067903

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IDEAYA Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001676725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474268251
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38915
- **FILM NUMBER:** 23725335

**BUSINESS ADDRESS:**
- **STREET 1:** 7000 SHORELINE COURT, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-443-6209

**MAIL ADDRESS:**
- **STREET 1:** 7000 SHORELINE COURT, SUITE 350
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ideaya Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20160609

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 10, 2023

------

## IDEAYA Biosciences, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38915** | **47-4268251** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br> **Identification Number)** |

---

#### 7000 Shoreline Court, Suite 350

#### South San Francisco, California 94080

#### (Address of principal executive offices, including Zip Code)

#### Registrant's telephone number, including area code: (650) 443-6209

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | IDYA | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

#### Item 8.01. Other Events.
IDEAYA Biosciences, Inc. (the "Company") is aware that the Federal Deposit Insurance Corporation (the "FDIC") has announced that Silicon Valley Bank ("SVB") has been closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver.

The Company believes that there will be no material impact to its operations or cash runway guidance as a result of the FDIC action. Although the Company maintains an operating account at SVB, the amount of cash, cash equivalents or marketable securities subject to potential loss is a maximum of mid-single digit millions of dollars. The company has separate accounts at custodian banks and/or other banks, which collectively hold substantially all of the Company's cash, cash equivalents, and marketable securities, and which are held in the Company's name and are not directly exposed to any consequences of the SVB receivership.

#### Forward-Looking Statements
This current report contains forward-looking statements, including, but not limited to, statements related to the impact of the FDIC action on the Company's operations and cash runway. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K filed on March 7, 2023 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IDEAYA BIOSCIENCES, INC.** | **IDEAYA BIOSCIENCES, INC.** |
| Date: March 10, 2023 | By: | /s/ Yujiro Hata |
|  |  | Yujiro Hata |
|  |  | President and Chief Executive Officer |

---